Sun Pharmaceutical Q2 profit falls 47%
During the period under review, the company's sales in the US stood at USD 244 million, up by 38 per cent from same period of 2011-12 fiscal.
The company said its US-based unit Caraco resumed manufacturing at its facilities in Michigan during the quarter after the USFDA determined Caraco to be in compliance with relevant paragraphs of the Consent Decree.
Formulation sales in ROW markets outside of India and US accounted for USD 68 million during the second quarter, registering a growth of 21 per cent over the same period of 2011-12 fiscal, it added.
The company said during the second quarter four abbreviated new drug applications were filed with the US health regulator.
Shares of Sun Pharma today closed at Rs 696.15 apiece on the BSE, down 0.76 per cent from its previous close.
Be the first to comment.
